Amarin (AMRN)
(Delayed Data from NSDQ)
$0.59 USD
-0.01 (-1.80%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $0.60 +0.01 (1.16%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.59 USD
-0.01 (-1.80%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $0.60 +0.01 (1.16%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
Zacks News
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
by Zacks Equity Research
Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
by Zacks Equity Research
Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
by Zacks Equity Research
Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
by Zacks Equity Research
Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.
Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?
by Zacks Equity Research
Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect increasing patient days and admissions.
Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results are likely to reflect improved performances from the Acute Care Hospital Services and Behavioral Health Care Services businesses.
Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.
Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
Are Medical Stocks Lagging Amarin (AMRN) This Year?
by Zacks Equity Research
Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
by Zacks Equity Research
Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million. Stock gains.
Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Makes Amarin (AMRN) a New Buy Stock
by Zacks Equity Research
Amarin (AMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.
Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Amarin (AMRN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss
by Zacks Equity Research
Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.
Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall
by Zacks Equity Research
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.